Ralph Weichselbaum to Prostatic Neoplasms
This is a "connection" page, showing publications Ralph Weichselbaum has written about Prostatic Neoplasms.
Connection Strength
1.566
-
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther. 2011 Jul; 10(7):1185-93.
Score: 0.153
-
Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. Urology. 2006 May; 67(5):1007-11.
Score: 0.108
-
Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004 Aug; 45(8):1315-22.
Score: 0.096
-
Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004 Apr; 45(4):571-8.
Score: 0.093
-
Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med. 2004 Feb; 45(2):238-46.
Score: 0.092
-
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16).
Score: 0.089
-
Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):530-538.
Score: 0.074
-
Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
Score: 0.072
-
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999 May 01; 59(9):2055-8.
Score: 0.066
-
Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 02 01; 125(3):340-352.
Score: 0.065
-
Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998 Nov-Dec; 5(6):344-9.
Score: 0.064
-
Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Aug 30; 33(1):3-14.
Score: 0.051
-
Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol. 1991 Feb; 9(2):328-34.
Score: 0.037
-
Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol. 1991 Jan; 46(1):31-6.
Score: 0.037
-
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
Score: 0.036
-
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30.
Score: 0.034
-
Characterization of response to radiation mediated gene therapy by means of multimodality imaging. Magn Reson Med. 2009 Aug; 62(2):348-56.
Score: 0.034
-
Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat. 2009 Jun; 8(3):201-6.
Score: 0.033
-
Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer. 2009 Apr 15; 115(8):1784-90.
Score: 0.033
-
MUCing around with tumor suppression. Cancer Biol Ther. 2008 Dec; 7(12):1968-9.
Score: 0.032
-
Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1316-21.
Score: 0.030
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.024
-
Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int J Cancer. 2002 Feb 01; 97(4):410-5.
Score: 0.020
-
Evolution of toxicity after conformal radiotherapy for prostate cancer. Prostate Cancer Prostatic Dis. 2002; 5(4):296-303.
Score: 0.020
-
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71.
Score: 0.020
-
Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61.
Score: 0.019
-
Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. Urology. 1999 Nov; 54(5):875-9.
Score: 0.017
-
PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology. 1999 Oct; 54(4):700-5.
Score: 0.017
-
Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 1999 Jul-Aug; 5(4):230-6.
Score: 0.017
-
Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am. 1998 Jan-Feb; 4(1):27-34.
Score: 0.015
-
Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Feb 01; 37(3):551-7.
Score: 0.014
-
Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am. 1996 Jul-Aug; 2(4):225-33.
Score: 0.014
-
Radiation oncology. JAMA. 1996 Jun 19; 275(23):1852-3.
Score: 0.014
-
Measurement of weekly prostate specific antigen levels in patients receiving pelvic radiotherapy for nonprostatic malignancies. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):189-95.
Score: 0.013
-
Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec; 1(7):541-5.
Score: 0.011
-
Differing patterns of cytotoxicity of the phorbol ester 12-O-tetradecanoylphorbol 13-acetate in various human cell strains. Carcinogenesis. 1985 Dec; 6(12):1703-8.
Score: 0.002